PISCATAWAY, N.J., June 9 /PRNewswire/ -- Sabinsa Corporation has issued a position paper on the safety of HCA as found in its branded ingredient products, specifically the Citrin(R) range of extracts and GarCitrin(R). This paper, which reviews and analyzes the published safety documentation of Garcinia cambogia extract, its active component hydroxycitric acid and its salts, is available to download from http://www.sabinsa.com and http://www.garcitrin.com.
On May 1, 2009, the FDA issued a warning to consumers, based on adverse event reports, to stop using Hydroxycut products by Iovate Health Sciences Inc., of Oakville, Ontario and distributed by Iovate Health Sciences USA Inc. of Blasdell, NY. Although branded ingredients from Sabinsa Corporation do not occur in Hydroxycut, our scientific integrity dictates that we dispel any reservations on the safety of a healthful, natural, food ingredient, hydroxycitric acid, which forms a part of the active ingredients composition of Hydroxycut.
The active ingredients in an example product in the Hydroxycut line include Garcinia cambogia fruit rind extract (supplying calcium hydroxycitrate and potassium hydroxycitrate); Chromium polynicotinate; Gymnema sylvestre leaf extract; caffeine; Green tea extract (supplying polyphenols, catechins, 15% w/w epigallocatechin gallate (EGCG); White tea extract (supplying polyphenols, catechins, 15% w/w epigallocatechin gallate (EGCG); Oolong tea extract supplying polyphenols, catechins, 15% w/w epigallocatechin gallate (EGCG); Ginger extract (supplying gingerols); Raspberry ketone; and Quercetin dihydrate.
Based on the long history of food use of Garcinia cambogia fruits, the wealth of literature encompassing both preclinical and clinical studies, Sabinsa Corporation's clinical experience with Citrin(R) and 15 years of successful marketing of Citrin(R) extracts, there is no direct epidemiological or clinical evidence linking Garcinia cambogia fruit rind extract with hepatotoxicity. An exhaustive safety review by an independent panel of experts established GRAS-affirmed status for Citrin(R)K, the potassium salt of hydroxycitric acid, in 2007. The safety of G. cambogia extract and its active ingredient (-)-HCA is supported by a variety of animal as well as in vitro experimental studies. Additional evidence from multiple human clinical trials further supports the safety aspects of (-)-HCA. Because of its potential health benefits, there has been considerable effort to elucidate the mechanism of action of (-)-HCA. Relevant biological and toxicological studies on G. cambogia extract and (-)-HCA supporting the safety in use of Citrin(R)K are included in the report.
Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 20 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher, with many certified Halal. For more information, visit http://www.sabinsa.com and http://www.garcitrin.com.
MEDIA CONTACT: Hame Persaud email@example.com T: 732-777-1111
|SOURCE Sabinsa Corporation|
Copyright©2009 PR Newswire.
All rights reserved